NCT02475213 Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer Status COMPLETED Phase PHASE1
NCT02426125 A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Status COMPLETED Phase PHASE3
NCT02365766 Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects Status COMPLETED Phase PHASE1/PHASE2
NCT02278978 BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma Status UNKNOWN Phase PHASE2
NCT02236195 Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes Status COMPLETED Phase PHASE2
NCT02232646 A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies Status WITHDRAWN Phase PHASE2
NCT01993966 EGCG Modulate the Cytotoxic Effects of Chemotherapeutic Agents in Human Urothelial Carcinoma Cells Status UNKNOWN Phase N/A
NCT01907308 Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma Status WITHDRAWN Phase PHASE2
NCT01844947 Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract Status COMPLETED Phase PHASE1
NCT01780545 Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer Status COMPLETED Phase PHASE2
NCT01606345 Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma Status COMPLETED Phase PHASE1
NCT01600339 A Trial of Cabazitaxel for Advanced Transitional Cell Carcinoma (TCC) Status COMPLETED Phase PHASE2
NCT01524991 First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma Status COMPLETED Phase PHASE2
NCT01437488 Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy Status COMPLETED Phase PHASE2
NCT01366144 Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT01353222 DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma Status TERMINATED Phase PHASE2